Research graph
References from Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity. Local targets link to admitted publications; unresolved targets remain external evidence.
Long COVID science, research and policy
10.1038/s41591-024-03173-6 · 2024 · External reference
Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations
10.1016/s2213-2600(23)00239-4 · 2023 · External reference
Postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras
10.1056/nejmoa2403211 · 2024 · External reference
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
10.1126/science.abl4784 · 2021 · External reference
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
10.1038/s41467-024-54462-0 · 2024 · External reference
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
10.1126/science.adm9724 · 2024 · External reference
Non-covalent inhibitors of SARS-CoV-2 Papain-Like protease (PLpro): in vitro and in vivo antiviral activity
10.1021/acs.jmedchem.4c00378 · 2024 · External reference
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
10.1038/s41586-020-2286-9 · 2020 · External reference
The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?
2022 · External reference
Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial
10.1001/jamanetworkopen.2023.54991 · 2024 · External reference
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
10.1038/s41586-020-2601-5 · 2020 · External reference
The substrate selectivity of papain-like proteases from human-infecting coronaviruses correlates with innate immune suppression
10.1126/scisignal.ade1985 · 2023 · External reference
SARS-CoV-2 papain-like protease activates nociceptors to drive sneeze and pain
2024 · External reference
Mechanism and inhibition of the Papain-Like protease, PLpro, of SARS-CoV-2
10.15252/embj.2020106275 · 2020 · External reference
Insights into drug repurposing, as well as specificity and compound properties of piperidine-based SARS-CoV-2 PLpro inhibitors
10.3389/fchem.2022.861209 · 2022 · External reference
A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
10.1073/pnas.0805240105 · 2008 · External reference
X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases
10.1021/jm401712t · 2014 · External reference
Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape
10.1038/s41467-024-50566-9 · 2024 · External reference
Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
10.1126/sciadv.ado4288 · 2024 · External reference
Non-covalent inhibitors of SARS-CoV-2 Papain-Like protease (PLpro): in vitro and in vivo antiviral activity
10.1021/acs.jmedchem.4c00378 · 2024 · External reference
Discovery and characterization of novel potent non-covalent small molecule inhibitors targeting papain-like protease from SARS-CoV-2
10.1016/j.apsb.2024.04.011 · 2024 · External reference
Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-cov-2 PLpro
10.1016/j.antiviral.2024.105944 · 2024 · External reference
Structure-based design of covalent SARS-CoV-2 Papain-Like protease inhibitors
10.1021/acs.jmedchem.4c01872 · 2024 · External reference
Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates
10.1038/s41467-025-56902-x · 2025 · External reference
Unresolved reference
2024 · External reference
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID
10.1038/s41467-025-57905-4 · 2025 · External reference
Discovery of SARS-CoV-2 Papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay
10.1021/acscentsci.1c00519 · 2021 · External reference
Inhibitor induced conformational changes in SARS-COV-2 papain-like protease
10.1038/s41598-022-15181-y · 2022 · External reference
DiMSum: an error model and pipeline for analyzing deep mutational scanning data and diagnosing common experimental pathologies
10.1186/s13059-020-02091-3 · 2020 · External reference
Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin
10.1038/s41467-023-38031-5 · 2023 · External reference
GISAID’s role in pandemic response
10.46234/ccdcw2021.255 · 2021 · External reference
Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like protease
10.1038/s41467-025-59922-9 · 2025 · External reference
A new coronavirus associated with human respiratory disease in China
10.1038/s41586-020-2008-3 · 2020 · External reference
Contributions of hyperactive mutations in Mpro from SARS-CoV-2 to drug resistance
10.1021/acsinfecdis.3c00560 · 2024 · External reference
Therapeutic strategies for COVID-19: progress and lessons learned
10.1038/s41573-023-00672-y · 2023 · External reference
Accelerating antiviral drug discovery: lessons from COVID-19
10.1038/s41573-023-00692-8 · 2023 · External reference
The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery
10.1038/s41467-020-20718-8 · 2021 · External reference
Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV
10.1021/cb500917m · 2015 · External reference
Comparison of SARS and NL63 papain-like protease binding sites and binding site dynamics: inhibitor design implications
10.1016/j.jmb.2011.09.030 · 2011 · External reference
Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes
10.1093/nar/gku511 · 2014 · External reference
Lentiviral co-packaging mitigates the effects of intermolecular recombination and multiple integrations in pooled genetic screens
2018 · External reference
Cutadapt removes adapter sequences from high-throughput sequencing reads
10.14806/ej.17.1.200 · 2011 · External reference
UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy
10.1101/gr.209601.116 · 2017 · External reference
SeqKit2: A Swiss army knife for sequence and alignment processing
10.1002/imt2.191 · 2024 · External reference
